Scientific reports, 2020-10, Vol.10 (1), p.17187-17187, Article 17187
2020
Details
- Autor(en) / Beteiligte
- Titel
- Synthetic anticoagulant heparan sulfate attenuates liver ischemia reperfusion injury
- Ist Teil von
- Scientific reports, 2020-10, Vol.10 (1), p.17187-17187, Article 17187
- Ort / Verlag
- England: Nature Publishing Group UK
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Heparan sulfate (HS) is a sulfated glycosaminoglycan abundant on the cell surface and in the extracellular matrix and has several biological activities including anticoagulation and anti-inflammation. Liver ischemia reperfusion injury is associated with coagulation and inflammatory responses. Here, we synthesized HS oligosaccharides with defined sulfation patterns and show that synthetic anticoagulant HS oligosaccharides limit liver ischemia reperfusion injury in a mouse model. Using a small targeted HS library, we demonstrate that an oligosaccharide that possesses both anticoagulant activity and binding affinity to HMGB1, the inflammatory target, decreases injury greater than oligosaccharides that only bind to HMGB1 or only have anticoagulant activity. HS oligosaccharides may represent a potential new therapeutic option for decreasing liver damage resulting from ischemia reperfusion injury.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2045-2322eISSN: 2045-2322DOI: 10.1038/s41598-020-74275-7Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7566620
- Format
- –
- Schlagworte
- Animals, Anticoagulants - pharmacology, Blood Coagulation - drug effects, Extracellular Matrix - drug effects, Extracellular Matrix - metabolism, Heparitin Sulfate - pharmacology, HMGB1 Protein - metabolism, Liver - drug effects, Liver - metabolism, Liver Diseases - drug therapy, Liver Diseases - metabolism, Male, Mice, Mice, Inbred C57BL, Oligosaccharides - pharmacology, Reperfusion Injury - drug therapy, Reperfusion Injury - metabolism